Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer
The Oncologist · 2023
DOI: 10.1093/oncolo/oyad058 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Oncologist, 2023. Verfasst von Ravi A Madan und 20 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Institute, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
Background
Before 2018, there was no standard of care for non-metastatic (M0) castration resistant prostate cancer nmCRPC. Androgen receptor antagonists (ARAs) were commonly used sequentially nmCRPC.
Methods
This was a multicenter, randomized clinical trial comparing the ARA flutamide+/−PROSTVAC, a pox viral vaccine targeting PSA that includes T-cell co-stimulatory molecules. Eligible men had negative CT and Tc99 bone scans, and rising PSA on ADT. Previous treatment with ARA was a stratification factor. Patients were also evaluated for antigen-specific immune responses using intracellular cytokine staining.
Results
Thirty-three patients randomized to flutamide and 31 to flutamide+vaccine. The median age was 71.8 and 69.8 years, respectively. The median time to treatment failure after a median potential follow-up of 46.7 months was, 4.5 months (range 2-70) for flutamide alone vs. 6.9 months (2.5-40; P = .38) with flutamide+vaccine. Seven patients in each arm had a >50% PSA response. Antigen-specific responses were similar in both arms (58% of patients in flutamide alone and 56% in flutamide+vaccine). The treatments were well tolerated. The most common side effect > grade 2 was injection site reaction seen in 29/31 vaccine patients which were self-limiting.
Conclusion
The combination of flutamide+PROSTVAC did not improve outcomes in men with nmCRPC compared with flutamide alone. (ClinicalTrials.gov Identifier: NCT00450463)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Cancer Institute, Bethesda, MD, USA.
- Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA.
- Department of Hematology/Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA.
- Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
ORCID-Profile: Julius Strauss, Jeffrey Schlom
Förderung
- National Cancer Institute
Zitieren
APA
Madan, R. A., Bilusic, M., Stein, M. N., Donahue, R. N., Arlen, P. M., Karzai, F., Plimack, E., Wong, Y. N., Geynisman, D. M., Zibelman, M., Mayer, T., Strauss, J., Chen, G., Rauckhorst, M., McMahon, S., Couvillon, A., Steinberg, S., Figg, W. D., Dahut, W. L., …, & Gulley, J. L. (2023). Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyad058
Vancouver
Madan RA, Bilusic M, Stein MN, Donahue RN, Arlen PM, Karzai F, et al. Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. The Oncologist. 2023. doi:10.1093/oncolo/oyad058
BibTeX
@article{Madan2023,
author = {Madan, Ravi A and Bilusic, Marijo and Stein, Mark N and Donahue, Renee N and Arlen, Philip M and Karzai, Fatima and Plimack, Elizabeth and Wong, Yu-Ning and Geynisman, Daniel M and Zibelman, Matthew and Mayer, Tina and Strauss, Julius and Chen, Gang and Rauckhorst, Myrna and McMahon, Sheri and Couvillon, Anna and Steinberg, Seth and Figg, William D and Dahut, William L and Schlom, Jeffrey and Gulley, James L},
title = {Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyad058}
}
EUVIMED